MA63141B1 - Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant - Google Patents

Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant

Info

Publication number
MA63141B1
MA63141B1 MA63141A MA63141A MA63141B1 MA 63141 B1 MA63141 B1 MA 63141B1 MA 63141 A MA63141 A MA 63141A MA 63141 A MA63141 A MA 63141A MA 63141 B1 MA63141 B1 MA 63141B1
Authority
MA
Morocco
Prior art keywords
crystalline form
derivative compound
tricyclic derivative
pharmaceutical composition
preparation process
Prior art date
Application number
MA63141A
Other languages
English (en)
Other versions
MA63141A1 (fr
Inventor
John Kim
Seong Hyeon Jeon
Jung Gi An
Original Assignee
Onconic Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc. filed Critical Onconic Therapeutics Inc.
Publication of MA63141A1 publication Critical patent/MA63141A1/fr
Publication of MA63141B1 publication Critical patent/MA63141B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

 La présente invention concerne : une forme cristalline d'un sel d'acide citrique d'un composé dérivé tricyclique représenté par la formule chimique 1 ; un procédé de préparation de la forme cristalline du sel d'acide citrique ; et une forme cristalline du composé dérivé tricyclique représenté par la formule chimique 1, la forme cristalline du composé dérivé tricyclique étant utilisée de manière efficace dans la préparation de la forme cristalline du sel d'acide citrique.
MA63141A 2021-05-18 2022-05-18 Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant MA63141B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210064416 2021-05-18
PCT/KR2022/007101 WO2022245125A1 (fr) 2021-05-18 2022-05-18 Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant

Publications (2)

Publication Number Publication Date
MA63141A1 MA63141A1 (fr) 2024-09-30
MA63141B1 true MA63141B1 (fr) 2026-03-31

Family

ID=84140601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63141A MA63141B1 (fr) 2021-05-18 2022-05-18 Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant

Country Status (16)

Country Link
US (1) US20240246933A1 (fr)
EP (1) EP4342898A4 (fr)
JP (2) JP7809725B2 (fr)
KR (1) KR102918032B1 (fr)
CN (1) CN117321054A (fr)
BR (1) BR112023023813A2 (fr)
CA (1) CA3219303A1 (fr)
CL (1) CL2023003335A1 (fr)
CO (1) CO2023015293A2 (fr)
EC (1) ECSP23086661A (fr)
IL (1) IL308326A (fr)
MA (1) MA63141B1 (fr)
MX (1) MX2023013624A (fr)
PE (1) PE20241190A1 (fr)
UA (1) UA130395C2 (fr)
WO (1) WO2022245125A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115535A1 (fr) * 2012-02-01 2013-08-08 제일약품주식회사 Nouveau sel d'addition d'acide cristallin d'un composé d'un dérivé tricyclo ou d'un hydride de celui-ci et son procédé de production
WO2016200101A2 (fr) * 2015-06-09 2016-12-15 제일약품주식회사 Composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique le contenant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) * 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
US9907357B2 (en) 2015-09-24 2018-03-06 Nike, Inc. Fluid-filled chamber for an article of footwear
CN107955001A (zh) * 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115535A1 (fr) * 2012-02-01 2013-08-08 제일약품주식회사 Nouveau sel d'addition d'acide cristallin d'un composé d'un dérivé tricyclo ou d'un hydride de celui-ci et son procédé de production
WO2016200101A2 (fr) * 2015-06-09 2016-12-15 제일약품주식회사 Composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
ECSP23086661A (es) 2023-12-29
WO2022245125A1 (fr) 2022-11-24
MX2023013624A (es) 2023-11-30
CN117321054A (zh) 2023-12-29
PE20241190A1 (es) 2024-06-03
KR102918032B1 (ko) 2026-01-27
CA3219303A1 (fr) 2022-11-24
EP4342898A1 (fr) 2024-03-27
EP4342898A4 (fr) 2024-09-11
IL308326A (en) 2024-01-01
CL2023003335A1 (es) 2024-06-21
BR112023023813A2 (pt) 2024-02-06
UA130395C2 (uk) 2026-02-04
CO2023015293A2 (es) 2023-11-20
US20240246933A1 (en) 2024-07-25
JP7809725B2 (ja) 2026-02-02
JP2025186544A (ja) 2025-12-23
MA63141A1 (fr) 2024-09-30
KR20230157374A (ko) 2023-11-16
JP2024519334A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
CA2373834C (fr) Procede pour la production de thiazolidine
US4122193A (en) Drugs or medicines for influencing the central nervous system
CA2441613C (fr) Nouvel amlodipine camsylate et son procede de preparation
MA63141B1 (fr) Forme cristalline de composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique la comprenant
RU2007136782A (ru) Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины
EP0086453B1 (fr) Dérivés de thiazaspiro, procédé pour leur préparation et compositions pharmaceutiques les contenant
US2625567A (en) 1-benzyloxy-2-alkylaminoindanes
Henry et al. N-Chloromorpholine and Related Compounds1
FR2669030A1 (fr) Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20010098478A (ko) 사이클로프로펜 제조 방법
ES2352926B1 (es) Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos.
US2827471A (en) Process for preparing long-chain trifluoroalkanoic acids
KR101093866B1 (ko) 티옥트산의 엘-카르니틴과의 염기성 염
EP3842418A1 (fr) Procédé de purification de cystéamine
EP3386943B1 (fr) Procédés de réduction de la couleur de compositions d'alcanolamine
ES2352927B1 (es) Compuestos deuterados de 5-trideuterometil-6-metil-2-tioxo-2,3-dihidropiridin-4(1h)-ona y procedimiento de preparación de los mismos.
Walter 4, 4', 4 ″-Trinitrotriphenylamine1
JPS591457A (ja) ベンズヒドリルスルフイニルエチルアミン誘導体
Baker et al. The purification of phenothiazine
Basterfield et al. Acyl Iso-Ureas
DE976155C (de) Verfahren zur Herstellung von Phenthiazinderivaten und ihren Salzen
WO2022184611A1 (fr) Procédé de préparation d'alkyl-4-oxotétrahydrofuran-2-carboxylate
DE1443403C (de) N Cyclopropyl 1 aminoindan Derivate und Verfahren zu ihrer Herstellung
JPS6256871B2 (fr)
FR2517676A1 (fr) Nouveaux derives tetrazoliques substitues en position 5, leur procede de preparation et leur application en therapeutique